Evidence map›Paper›PMID 36777324›Full record

ArticleLancet regional health. Americas2022

Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study.

Abel B Quaresma, Aderson O M C Damiao, Claudio S R Coy, Daniela O Magro, Adriano A F Hino, Douglas A Valverde, Remo Panaccione, Stephanie B Coward, Siew C Ng, Gilaad G Kaplan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet regional health. Americas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Crotoxin fromFrontiers in immunology · 2026
    Article
  12. Article
  13. The global burden of inflammatory bowel disease: from 2025 to 2045.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Diet as an epigenetic factor in inflammatory bowel disease.World journal of gastroenterology · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abel B QuaresmaUniversidade do Oeste de Santa Catarina, UNOESC, Colorectal Surgery, Joaçaba, Brazil.
Aderson O M C DamiaoUniversity of Sao Paulo, Gastroenterology, São Paulo, Brazil.
Claudio S R CoyUniversity of Campinas UNICAMP, Colorectal Surgery Unit, Campinas, Brazil.
Daniela O MagroUniversity of Campinas UNICAMP, Colorectal Surgery Unit, Campinas, Brazil.
Adriano A F HinoCatholic University of Paraná, Health Sciences Postgraduate Program, Curitiba, Brazil.
Douglas A ValverdeTechtrials Healthcare, Data Science, Vinhedo, Brazil.
Remo PanaccioneUniversity of Calgary, Department of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada.
Stephanie B CowardUniversity of Calgary, Department of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada.
Siew C NgDepartment of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Diseases, LKS Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Gilaad G KaplanUniversity of Calgary, Department of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada.
Paulo G KotzeCatholic University of Paraná, Health Sciences Postgraduate Program, Curitiba, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Population-based data on epidemiology of Inflammatory Bowel Diseases (IBD) in Brazil are scarce. This study aims to define temporal trends of incidence and prevalence rates of Crohn's disease (CD) and ulcerative colitis (UC) in Brazil. Methods: All IBD patients from the public healthcare national system were included from January 2012 to December 2020. Average Annual Percent Change (AAPC) and 95% confidence intervals (CI) were calculated using log-linear regression for incidence and binomial regression for prevalence. Moran's I autocorrelation index was used to analyse clustering of cities by level of prevalence. Findings: A total of 212,026 IBD patients were included. Incidence of IBD rose from 9.4 in 2012 to 9.6 per 100,000 in 2020 (AAPC=0.8%; 95% CI -0.37, 1.99); for UC, incidence increased from 5.7 to 6.9 per 100,000 (AAPC=3.0%; 95% CI 1.51, 4.58) and for CD incidence decreased from 3.7 to 2.7 per 100,000 (AAPC=-3.2%; 95% CI -4.45, -2.02). Prevalence of IBD increased from 30.0 in 2012 to 100.1 per 100,000 in 2020 (AAPC=14.8%; CI 14.78-14.95); for UC, from 15.7 to 56.5 per 100,000 (AAPC=16.0%; CI 15.94, 16.17); for CD from 12.6 to 33.7 per 100,000 (AAPC=12.1% CI 11.95, 12.02). A south-north gradient was observed in 2020 prevalence rates of IBD [I=0.40 (p<0.0001)], CD [I=0.22 (p<0.0001)] and UC [I=0.42 (p<0.0001)]. Interpretation: Incidence of CD is decreasing whereas of UC is increasing, leading to stabilization in the incidence of IBD from 2012 to 2020 in Brazil. Prevalence of IBD has been climbing with 0.1% of Brazilians living with IBD in 2020. Funding: None.

Indexed as

AAPC, Average Annual Percent ChangeAC, AcreAL, AlagoasAM, AmazonasAP, AmapáBA, BahiaBrazilCAAE, Certificate of Presentation for Ethical AppreciationCD, Crohn's diseaseCE, CearáCI, confidence intervalsCrohn's diseaseDATASUS, Department of Health Informatics/Ministry of HealthDF, Distrito federalEpidemiologyES, Espírito SantoGO, GoiásIBD, Inflammatory Bowel DiseasesIBDU, Inflammatory Bowel Diseases undeterminedIBGE, National Institute of Geographics and Statistics (Instituto Brasileiro de Geografia e Estatística)ICD-10, Classification of Diseases and Related Health Problems, Tenth RevisionIncidenceInflammatory bowel diseaseMA, MaranhãoMG, Minas GeraisMS, Mato Grosso do SulMT, Mato GrossoPA, ParáPB, ParaíbaPE, PernambucoPI, PiauíPrevalencePR, ParanáRN, Rio Grande do NorteRO, RondôniaRR, RoraimaRS, Rio Grande do SulSC, Santa CatarinaSE, SergipeSP, São PauloSUS, national public health system (Sistema Único de Saúde)TO, TocantinsUC, ulcerative colitisUlcerative colitisUNOESC, University of the West of Santa Catarina

Identifiers

PMID36777324
PMCPMC9903988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.